NCT05423522 - Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

January 23, 2024

Study Completion Date

October 29, 2024

Conditions

Alzheimer's Disease

Interventions

DRUG

NanoLithium® NP03

One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.

DRUG

Placebo

One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.

Trial Locations (8)

Hôpital De La Timone, Marseille

CHU Toulouse - Hôpital La Grave - Cité de la Santé, Toulouse

CHU de Montpellier - Hôpital Gui de Chauliac, Montpellier

CHU de Lille, Lille

Hôpital Universitaire de Strasbourg, Strasbourg

Hôpital des Charpennes - Hospices Civils de Lyon, Villeurbanne

Hôpital Lariboisière, Paris

CHU de Limoges - Hôpital Dupuytren, Limoges